NeuroPace, Inc. (NPCE) is a publicly traded company in the Healthcare — Medical - Devices industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories.
Analysis Summary
NeuroPace, Inc. reported revenue of $100.0M in the most recent fiscal year, growing at a 5-year CAGR of 19.4%.
Trailing-twelve-month margins: gross margin 79.6%, operating margin -15.3%, net margin -19.3%.
At the current price of $14.10, NPCE has negative trailing earnings (P/E not meaningful) and an ROE of -119.68%. Market capitalisation stands at $481M.
Balance sheet quality for NPCE: current ratio of 5.3, net debt of $9.8M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $14.10 |
| Market Cap | $481M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 39.18 |
| EV / EBITDA | -43.63 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -119.68% |
| Return on Invested Capital | -18.43% |
| Return on Assets | -19.71% |
| Gross Margin | 79.63% |
| Operating Margin | -15.26% |
| Net Margin | -19.34% |
Financial Health
| Debt / Equity | 5.88 |
| Current Ratio | 4.94 |
| Piotroski F-Score | 5 |
| Altman Z-Score | -2.52 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NPCE | NeuroPace, Inc. | $481M | 39.18 | -119.7% | |
| ABT | Abbott Laboratories | $177.1B | 32.49 | 3.45 | 10.5% |
| 0Y6X.L | Medtronic Plc | $125.7B | |||
| MDT | Medtronic plc | $118.5B | 22.97 | 2.39 | 10.6% |
| SYK | Stryker Corporation | $109.2B | 29.95 | 4.66 | 16.4% |
| 0R2S.L | Stryker Corporation | $107.9B | 29.27 | 4.55 | 16.4% |
| 0HOY.L | Boston Scientific Corporation | $66.5B | 48.91 | 5.86 | 11.9% |
| BSX | Boston Scientific Corporation | $65.3B | 17.73 | 2.61 | 14.9% |
Price Performance
| 1 month | -2.56% |
| 3 months | -9.79% |
| Year-to-date | -8.68% |
| 1 year | +42.57% |
| 3 years | +74.50% |
| 5 years | -19.06% |
52-Week Range
| 52-week High | $19.60 |
| 52-week Low | $9.22 |
| Avg Volume (90d) | 183K |
Related companies: ALDX · BWAY · CERS · CVRX · DCTH · GNLX · MASS
Explore sector: Healthcare · Medical - Devices
More sections of NPCE: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks